Derek Blevins1, C Jean Choi2, Martina Pavlicova3, Diana Martinez4, John J Mariani4, John Grabowski5, Frances R Levin4. 1. Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, United States. Electronic address: derek.blevins@nyspi.columbia.edu. 2. Mental Health Data Science, New York State Psychiatric Institute, New York, NY, United States. 3. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, United States. 4. Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, United States. 5. Department of Psychiatry, University of Minnesota Twin Cities, Minneapolis, MN, United States.
Abstract
BACKGROUND:Amphetamines are a first-line treatment for ADHD and have shown promise for the treatment of cocaine use disorder (CUD), both alone and with comorbid ADHD. Impulsiveness is a key aspect of both ADHD and substance use disorders. We sought to understand the role of baseline impulsiveness in the treatment of comorbid CUD and ADHD. METHODS: In a post hoc analysis (N = 76) of a 14-week, double-blind, randomized, placebo-controlled trial of mixed amphetamine salts-extended release (MAS-ER) for comorbid ADHD and CUD, we examined the relationship between treatment response and participants' baseline Barratt Impulsiveness Scale (BIS-11) score by comparing those with scores below versus above the median. In the original trial, participants received daily 60 mg MAS-ER, 80 mg MAS-ER, or placebo, in conjunction with cognitive behavioral therapy. RESULTS: The odds of a cocaine-abstinent week over time were significantly greater in the high BIS group compared to the low BIS group, both when missing data was treated as missing (p = .0155; OR = 1.23, 95% CI: 1.13, 1.35 versus OR = 1.04, 95% CI: 0.95, 1.15) and when missing data was treated as cocaine-positive (p = .003; OR = 1.15, 95% CI: 1.06, 1.24 versus OR = 0.96, 95% CI: 0.88, 1.05). CONCLUSIONS: The results show an association between higher within-group trait impulsiveness, as measured by the BIS-11, and response to MAS-ER for CUD in a cohort with comorbid ADHD. This result further demonstrates that impulsiveness is an important factor when considering treatment options for patients with CUD and that higher baseline impulsiveness may predict response to treatment with psychostimulants for CUD.
RCT Entities:
BACKGROUND:Amphetamines are a first-line treatment for ADHD and have shown promise for the treatment of cocaine use disorder (CUD), both alone and with comorbid ADHD. Impulsiveness is a key aspect of both ADHD and substance use disorders. We sought to understand the role of baseline impulsiveness in the treatment of comorbid CUD and ADHD. METHODS: In a post hoc analysis (N = 76) of a 14-week, double-blind, randomized, placebo-controlled trial of mixed amphetamine salts-extended release (MAS-ER) for comorbid ADHD and CUD, we examined the relationship between treatment response and participants' baseline Barratt Impulsiveness Scale (BIS-11) score by comparing those with scores below versus above the median. In the original trial, participants received daily 60 mg MAS-ER, 80 mg MAS-ER, or placebo, in conjunction with cognitive behavioral therapy. RESULTS: The odds of a cocaine-abstinent week over time were significantly greater in the high BIS group compared to the low BIS group, both when missing data was treated as missing (p = .0155; OR = 1.23, 95% CI: 1.13, 1.35 versus OR = 1.04, 95% CI: 0.95, 1.15) and when missing data was treated as cocaine-positive (p = .003; OR = 1.15, 95% CI: 1.06, 1.24 versus OR = 0.96, 95% CI: 0.88, 1.05). CONCLUSIONS: The results show an association between higher within-group trait impulsiveness, as measured by the BIS-11, and response to MAS-ER for CUD in a cohort with comorbid ADHD. This result further demonstrates that impulsiveness is an important factor when considering treatment options for patients with CUD and that higher baseline impulsiveness may predict response to treatment with psychostimulants for CUD.
Authors: Cleo L Crunelle; Dick J Veltman; Katelijne van Emmerik-van Oortmerssen; Jan Booij; Wim van den Brink Journal: Drug Alcohol Depend Date: 2012-09-29 Impact factor: 4.492
Authors: Katelijne van Emmerik-van Oortmerssen; Geurt van de Glind; Wim van den Brink; Filip Smit; Cleo L Crunelle; Marije Swets; Robert A Schoevers Journal: Drug Alcohol Depend Date: 2011-12-30 Impact factor: 4.492
Authors: J Grabowski; H Rhoades; J Schmitz; A Stotts; L A Daruzska; D Creson; F G Moeller Journal: J Clin Psychopharmacol Date: 2001-10 Impact factor: 3.153
Authors: Jennie Z Ma; Bankole A Johnson; Elmer Yu; David Weiss; Frances McSherry; Jim Saadvandi; Erin Iturriaga; Nassima Ait-Daoud; Richard A Rawson; Mark Hrymoc; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Dennis Weis; Michael McCann; Tony Pham; Christopher Stock; Ruth Dickinson; Ahmed Elkashef; Ming D Li Journal: Drug Alcohol Depend Date: 2012-11-09 Impact factor: 4.492
Authors: Stephen T Higgins; Stacey C Sigmon; Conrad J Wong; Sarah H Heil; Gary J Badger; Robert Donham; Robert L Dantona; Stacey Anthony Journal: Arch Gen Psychiatry Date: 2003-10
Authors: Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-11-21 Impact factor: 4.492
Authors: Angélica M Claudino; Irismar R de Oliveira; José Carlos Appolinario; Táki A Cordás; Monica Duchesne; Rosely Sichieri; Josué Bacaltchuk Journal: J Clin Psychiatry Date: 2007-09 Impact factor: 4.384
Authors: Roberto Secades-Villa; Olaya García-Rodríguez; Stephen T Higgins; José R Fernández-Hermida; José L Carballo Journal: J Subst Abuse Treat Date: 2007-05-23